Literature DB >> 15817083

Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length.

Hiroshi Watanabe1, Masaomi Chinushi, Hirotaka Sugiura, Takashi Washizuka, Satoru Komura, Yukio Hosaka, Hiroshi Furushima, Hiroshi Watanabe1, Junichi Hayashi, Yoshifusa Aizawa.   

Abstract

INTRODUCTION: In patients with Brugada syndrome, implantable cardioverter defibrillator (ICD) is the only reliable treatment to prevent sudden death though, in some cases, internal defibrillation may be unsuccessful. The aim of this study was to examine the determinants of defibrillation failure, with a focus on electrophysiologic characteristics.
METHODS: The study included 51 patients treated with ICD: 22 with Brugada syndrome and 29 with structural heart disease (SHD). The prevalence of defibrillation energy requirement precluding the programming of a 10-J safety margin, the mean right ventricular effective refractory period (ERP), and mean induced ventricular fibrillation cycle length (VFCL) from the stored ICD electrograms, were compared between the two patient groups.
RESULTS: High defibrillation requirements were observed in 18% of patients with Brugada syndrome versus 0% of patients with SHD. However, the patients with SHD had larger heart size than those with Brugada syndrome. Mean VFCL and mean ERP were both significantly shorter in patients with Brugada syndrome than in patients with SHD, and ERP and VFCL were significantly correlated.
CONCLUSION: Patients with Brugada syndrome have a high prevalence of high defibrillation energy requirement, and short ventricular ERP and VFCL.

Entities:  

Mesh:

Year:  2005        PMID: 15817083     DOI: 10.1046/j.1540-8167.2005.40579.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  7 in total

Review 1.  Brugada Syndrome:Risk Stratification And Management.

Authors:  Yoshifusa Aizawa
Journal:  J Atr Fibrillation       Date:  2016-10-31

2.  Long-time "real-life" performance of the subcutaneous ICD in patients with electrical heart disease or idiopathic ventricular fibrillation.

Authors:  Gerrit Frommeyer; Dirk G Dechering; Simon Kochhäuser; Markus Bettin; Julia Köbe; Lars Eckardt; Florian Reinke
Journal:  J Interv Card Electrophysiol       Date:  2016-05-23       Impact factor: 1.900

3.  Echocardiographic predictors of ventricular tachycardia.

Authors:  John N Catanzaro; John N Makaryus; Amgad N Makaryus; Cristina Sison; Christos Vavasis; Dali Fan; Ram Jadonath
Journal:  Clin Med Insights Cardiol       Date:  2015-03-12

4.  Tachyarrhythmia Cycle Length in Appropriate versus Inappropriate Defibrillator Shocks in Brugada Syndrome, Early Repolarization Syndrome, or Idiopathic Ventricular Fibrillation.

Authors:  Woo Seok Lee; Jun Kim; Chang-Hee Kwon; Jin Hee Choi; Uk Jo; Yoo Ri Kim; Gi-Byoung Nam; Kee-Joon Choi; You-Ho Kim
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

5.  Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.

Authors:  Boris Rudic; Erol Tülümen; Veronika Berlin; Susanne Röger; Ksenija Stach; Volker Liebe; Ibrahim El-Battrawy; Christina Dösch; Theano Papavassiliu; Ibrahim Akin; Martin Borggrefe; Jürgen Kuschyk
Journal:  J Am Heart Assoc       Date:  2017-10-17       Impact factor: 5.501

6.  Termination of ventricular tachycardia with antitachycardia pacing after ineffective shock therapy in an ICD recipient with hypertrophic cardiomyopathy.

Authors:  Panagiotis N Margos; Rolf Schomburg; Jorg Kynast; Ahmed A Khattab; Gert Richardt
Journal:  Indian Pacing Electrophysiol J       Date:  2009-01-07

7.  Scn3b knockout mice exhibit abnormal ventricular electrophysiological properties.

Authors:  Parvez Hakim; Iman S Gurung; Thomas H Pedersen; Rosemary Thresher; Nicola Brice; Jason Lawrence; Andrew A Grace; Christopher L-H Huang
Journal:  Prog Biophys Mol Biol       Date:  2009-01-24       Impact factor: 3.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.